Li, Chuang http://orcid.org/0000-0002-2809-4948
Huang, Yongsheng http://orcid.org/0000-0002-6114-7730
Fan, Qianqian http://orcid.org/0000-0003-3870-5869
Quan, Hongyang
Dong, Yeqing http://orcid.org/0000-0003-3094-2827
Nie, Meng http://orcid.org/0000-0003-2267-5810
Wang, Jiaqi http://orcid.org/0000-0002-0437-3811
Xie, Fucun http://orcid.org/0000-0002-5507-7596
Ji, Jiang http://orcid.org/0000-0001-9974-8171
Zhou, Lan http://orcid.org/0000-0001-8831-9152
Zheng, Zhi
Wang, Lin http://orcid.org/0000-0003-0307-7719
Funding for this research was provided by:
Ministry of Science and Technology of the People’s Republic of China (2016YFC1302203, 2016YFC1302203)
Ministry of Science and Technology of the People’s Republic of China
National Natural Science Foundation of China (81550019, 81550019)
Natural Science Foundation of Beijing Municipality (16G10825)
Article History
Received: 10 May 2020
Revised: 2 February 2021
Accepted: 15 February 2021
First Online: 17 March 2021
Ethics approval and consent to participate
: Human breast, colon, liver and pancreatic cancer tissues, and breast tissue microarrays were from two commercial sources, Alenabio Inc (Xi’an, China) and Zhuoli Biotech (Shanghai, China). The patient informed consents were complete.
: All authors agree to the publication of the article.
: The authors declare no competing interests.